Wed, February 11, 2009
Tue, February 10, 2009
Mon, February 9, 2009
Sun, February 8, 2009
Fri, February 6, 2009
Thu, February 5, 2009
Wed, February 4, 2009
Tue, February 3, 2009
Mon, February 2, 2009
Sun, February 1, 2009
Sat, January 31, 2009
Fri, January 30, 2009
[ Fri, Jan 30th 2009 ] - Market Wire
Progen-Avexa Merger Update
Thu, January 29, 2009

The Medicines Company: The Medicines Company to Announce Fourth Quarter and Full Year 2008 Financial Results on Wednesday, Febr


//health-fitness.news-articles.net/content/2009/ .. ar-2008-financial-results-on-wednesday-febr.html
Published in Health and Fitness on Wednesday, February 4th 2009 at 15:32 GMT, Last Modified on 2009-02-04 15:33:22 by Market Wire   Print publication without navigation


PARSIPPANY, NJ--(Marketwire - February 4, 2009) - The Medicines Company (NASDAQ: [ MDCO ]) has scheduled its quarterly conference call for Wednesday, February 18, 2009 at 8:30 a.m. Eastern Time to discuss fourth quarter and full year 2008 financial results, operational developments, guidance and outlook for 2009.

The conference call will be available via phone and webcast. The dial in information is listed below:

 Domestic Dial In: 800-901-5226 International Dial In: 617-786-4513 Passcode for both dial in numbers: 24685928 

Replay is available from 11:30 a.m. Eastern Time following the conference call through March 4, 2009. To hear a replay of the call dial 888-286-8010 (domestic) and 617-801-6888 (international). Passcode for both dial in numbers is 28543782.

This call is being webcast and can be accessed at The Medicines Company website at [ www.themedicinescompany.com ].

MDCO-G

The Medicines Company (NASDAQ: [ MDCO ]) is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex® (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has an investigational antiplatelet agent, cangrelor, in late-stage development and a serine protease inhibitor, CU-2010, in early-stage development. The Company's website is [ www.themedicinescompany.com ].


Publication Contributing Sources

Similar Health and Fitness Publications